US Stock MarketDetailed Quotes
CRVO CervoMed
- 10.800
- +1.645+17.97%
Close Nov 29 13:00 ET
- 11.350
- +0.550+5.09%
Post 17:01 ET
89.14MMarket Cap-7463P/E (TTM)
11.500High9.160Low344.21KVolume9.270Open9.155Pre Close3.59MTurnover8.43%Turnover RatioLossP/E (Static)8.25MShares26.37952wk High1.95P/B44.09MFloat Cap5.85052wk Low--Dividend TTM4.08MShs Float3375000000.000Historical High--Div YieldTTM25.56%Amplitude4.140Historical Low10.442Avg Price1Lot Size
About CervoMed Company
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.
Company Profile
SymbolCRVO
Company NameCervoMed
Listing DateNov 9, 2016
Founded1995
CEODr. John J. Alam, M.D.
MarketNASDAQ
Employees8
Fiscal Year Ends12-31
Address20 Park Plaza,Suite 424
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02216
Phone1-617-744-4400
Websitehttp://www.cervomed.com
Company Executives
- Name
- Position
- Salary
- Dr. John J. Alam, M.D.
- Chief Executive Officer, President and Director
- 815.16K
- Dr. Robert Joseph Cobuzzi, Jr,PhD
- Chief Operating Officer and Director
- 703.12K
- William R. Elder
- General Counsel, Corporate Secretary, Chief Financial Officer and Principal Accounting Officer
- 468.35K
- Kelly Blackburn
- Senior Vice President, Clinical Development
- 465.74K
- Dr. Joshua S. Boger,PhD
- Chairman of the Board
- --
- Dr. Sylvie Gregoire,Pharm.D.
- Director
- 376.94K
- Jeffrey V. Poulton
- Independent Director
- 47.20K
- Dr. Marwan Noel Sabbagh, M.D.
- Independent Director
- 41.15K
- Jane H. Hollingsworth
- Independent Director
- 82.91K
- Frank Zavrl
- Independent Director
- 47.76K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
